GW Pharmaceuticals, Zelira Therapeutics and Roche Gather for In-Person Cannabinoid Derived Therapeutics Summit
The Only Conference Dedicated to the Development of Cannabinoid Pharmaceuticals
There are few therapeutics containing cannabinoids that have been approved by major regulatory authorities, with worldwide sales totalling only around $53m in 2018 according to Evaluate Pharma.
Epidiolex was only launched at the end of 2018 and is expected to have $1.7bn in sales in 2024 based on consensus forecasts. Despite ongoing discussions surrounding clinical effectiveness, there is no denying that cannabinoid medications still hold value as demonstrated by the recent acquisition of GW by Jazz Pharmaceuticals.
FDA to Present an Update on the “FDA Perspective on Regulation of Cannabis Products and Research”
This September 21 -23, drug developers including GW will converge online at 4th Annual Cannabinoid Derived Pharmaceuticals Summit, to further advance cannabinoid medications through different unique clinical strategies
During the Summit, GW’s Head of Public Policy, Alice Mead, will be sharing The Rise of GW: Keeping Patient Care as a Core Value. They will cover the 23-year journey from GW’s creation up to its acquisition by Jazz pharmaceuticals in 2021.
Attend this meeting to learn how to harness novel formulations, manufacturing systems and clinical strategies to advance your therapeutic to the next level.
Cannabinoid Derived Pharmaceuticals Summit, September 21-23, 2021 | Virtual Event
Across 3 packed days, 100+ experts will converge at the Cannabinoid Derived Pharmaceuticals Summit to share cutting-edge advances across various approaches to build robust clinical data to warrant advancement, reviewing the global regulatory roadmap to approval and accepted clinical endpoints and comparing different cannabinoid sourcing and manufacturing systems for synthetic, phyto and biosynthetic major and minor cannabinoids.
Attendees will have the opportunity to:
- Check out the brand-new agenda section titled Establishing a Robust Clinical Program to Achieve Approval. This new component features speakers from leading cannabinoid pharma companies such as Zelira Therapeutics, Incannex, CIITech, Oxford Cannabinoid Technologies and BOL Pharma, discussing the critical strategic decisions they made to gain an edge over the competition while finding new therapies to help patients with currently unmet clinical needs
- Meet new companies that are breaking into the cannabinoid field with novel technologies in our start-up carousel, where these companies will have a short presentation before being able to answer your questions
- An expanded Intellectual Property with greater depth and comprehensive coverage of how IP strategy can be improved and how effective prosecution/enforcement are important factors that influence success
- Benchmark your approach and share your research with colleagues from around the world during our panel and audience discussions
For more information, please visit www.international-cdp.com or email info@hansonwade.com.
About Hanson Wade
Hanson Wade works in highly specialised fields to provide unmatched depth and quality of content. They work in sectors where quality of information is the difference between success and failure. Their conferences span high growth fields from pioneering life sciences to technology-augmented construction and are built where rapid change leads to greater opportunity for those that are most informed.